Pila Pharma AB (publ) (STO:PILA)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.316
+0.130 (10.96%)
At close: Mar 4, 2026
Market Cap60.12M -44.9%
Revenue (ttm)1.13M +42.7%
Net Income-16.86M
EPS-0.62
Shares Out45.68M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume60,390
Average Volume129,073
Open1.202
Previous Close1.186
Day's Range1.124 - 1.324
52-Week Range1.024 - 4.095
Beta0.23
RSI48.45
Earnings DateFeb 10, 2026

About Pila Pharma AB

Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 1
Stock Exchange Nasdaq Stockholm
Ticker Symbol PILA
Full Company Profile

Financial Performance

In 2025, Pila Pharma AB's revenue was 1.13 million, an increase of 42.68% compared to the previous year's 789,889. Losses were -16.86 million, 50.0% more than in 2024.

Financial Statements